Crizotinib is an inhibitor for ALK (anaplastic lymphoma kinase), ROS1 (c-Ros oncogene 1), and MET tyrosine kinases, used in the treatment of non-small cell lung cancer (NSCLC) that is positive for one of these proteins. There are two doses—200 mg and 250 mg—each in a capsule form. Adults usually take 250 mg twice a day, with or without eating.
You’ll find the medication in bottles with 60 capsules each. This drug stops a bunch of protein kinases, which is how it works. Just to be clear, this drug is for folks with a certain kind of lung cancer who’ve tested positive for ALK or ROS1 changes.
Crizotinib is like a generic version of a popular drug, the kind that was once a brand name but now lots of companies make it.
